- Home
- BIRD vs CRDL Comparison
BIRD vs CRDL Comparison
Compare BIRD & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- CRDL
- Stock Information
- Founded
- BIRD 2015
- CRDL 2017
- Country
- BIRD United States
- CRDL Canada
- Employees
- BIRD N/A
- CRDL N/A
- Industry
- BIRD Apparel
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BIRD Consumer Discretionary
- CRDL Health Care
- Exchange
- BIRD Nasdaq
- CRDL Nasdaq
- Market Cap
- BIRD 99.0M
- CRDL 80.1M
- IPO Year
- BIRD 2021
- CRDL N/A
- Fundamental
- Price
- BIRD $10.50
- CRDL $1.24
- Analyst Decision
- BIRD Buy
- CRDL Strong Buy
- Analyst Count
- BIRD 2
- CRDL 3
- Target Price
- BIRD $9.50
- CRDL $9.33
- AVG Volume (30 Days)
- BIRD 103.8K
- CRDL 246.9K
- Earning Date
- BIRD 08-06-2025
- CRDL 08-11-2025
- Dividend Yield
- BIRD N/A
- CRDL N/A
- EPS Growth
- BIRD N/A
- CRDL N/A
- EPS
- BIRD N/A
- CRDL N/A
- Revenue
- BIRD $182,544,000.00
- CRDL N/A
- Revenue This Year
- BIRD N/A
- CRDL N/A
- Revenue Next Year
- BIRD $5.04
- CRDL N/A
- P/E Ratio
- BIRD N/A
- CRDL N/A
- Revenue Growth
- BIRD N/A
- CRDL N/A
- 52 Week Low
- BIRD $3.93
- CRDL $0.77
- 52 Week High
- BIRD $18.33
- CRDL $2.63
- Technical
- Relative Strength Index (RSI)
- BIRD 60.59
- CRDL 45.66
- Support Level
- BIRD $10.20
- CRDL $1.35
- Resistance Level
- BIRD $11.68
- CRDL $1.50
- Average True Range (ATR)
- BIRD 1.18
- CRDL 0.10
- MACD
- BIRD 0.10
- CRDL -0.02
- Stochastic Oscillator
- BIRD 61.09
- CRDL 18.50
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.